Dynamiker Biotechnology(Tianjin) Co., Ltd.

With the wide application of broad-spectrum antibiotics, corticosteroid, immunosuppressant, anti-tumor drugs, as well as the prevalence of AIDS and the development of organ transplantation, the Invasive Fungal Disease, with a high mortality, is increasing and complicated. The Invasive Aspergillosis (IA) is rapidly increasing and Aspergillus fumigatus is the major pathogenic fungus which occupies 80%~90% of IA ^[1]. The susceptible population is mainly people who receive immunosuppressive therapy, such as hematopoietic stem cell transplantation patients, hematic malignant carcinoma patients, solid organ transplantation patients, bone marrow transplantation patients as well as long-term chemotherapy, corticosteroid therapy patients and severe AIDS patients.

The clinical symptom of IA is non-specific. There are no identical features in CT scan and X-ray. The difficulty of early diagnosis and timely treatment results in a high mortality. The presence of IgG antibodies against Aspergillus fumigatus indicates a prior Aspergillus fumigatus infection and suggests immunity. A significant rise of IgG levels indicates an acute infection or a re-infection.

Dynamiker Aspergillus fumigatus IgG Assay is based on indirect Enzyme-linked Immunosorbent Assay (ELISA). It is used for the quantitative detection of Aspergillus fumigatus anti-galactomannan IgG antibodies in human serum or plasma, offering a diagnostic reference for Aspergillus fumigatus infection. The kit is intended for professional use only.